An announcement has been issued by B&K CORP-B (ASX: 02396) regarding a formal alteration to its corporate identity.
The company's registered Chinese name has been officially changed from "Huaren Biotechnology (Qingdao) Co., Ltd." to "Qingcheng New Drug Biotechnology (Qingdao) Co., Ltd.".
It is important to note that the company's English name remains completely unchanged.
This change will be implemented in the market starting from 9:00 a.m. on July 22, 2026.
From that time, the Chinese trading abbreviation for the company's shares on the stock exchange will be updated from "Huaren Bio-B" to "Qingcheng New Drug-B".
The English trading abbreviation will continue to be "B&K CORP-B" and the company's stock code will also remain the same at "2396".
Comments